Editorial
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Dec 16, 2024; 12(35): 6782-6790
Published online Dec 16, 2024. doi: 10.12998/wjcc.v12.i35.6782
Cytokine release syndrome induced by anti-programmed death-1 treatment in a psoriasis patient: A dark side of immune checkpoint inhibitors
José Luis Maldonado-García, Ana Fragozo, Lenin Pavón
José Luis Maldonado-García, Departamento de Bioquímica, Facultad de Medicina, Universidad Nacional Autónoma de México, Coyoacán 04510, Ciudad de México, Mexico
José Luis Maldonado-García, Departamento de Inmunología, Escuela Nacional de Ciencias Biológicas, Mexico City 1134, Ciudad de México, Mexico
Ana Fragozo, Unidad de Desarrollo e Investigación en Bioterapéuticos, Escuela Nacional de Ciencias Biológicas, Instituto Politécnico Nacional, Mexico City 11340, Ciudad de México, Mexico
Lenin Pavón, Laboratorio de Psicoinmunología, Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz, Mexico City 11340, Mexico
Author contributions: Pavón L and Maldonado-García JL collaborated in designing the general concept and structure of the manuscript. Fragozo A, Maldonado-Garcia JL, and Pavón L wrote and edited the manuscript and reviewed the literature. Fragozo A and Maldonado-García JL designed the figure.
Supported by Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz, No. NC23189.0.
Conflict-of-interest statement: All authors declare that there are no conflicts of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Lenin Pavón, PhD, Professor, Laboratorio de Psicoinmunología, Instituto Nacional de Psiquiatría Ramón de la Fuente Muñiz, 101 Calzada México-Xochimilco, Mexico City 11340, Mexico. lkuriaki@inprf.gob.mx
Received: July 31, 2024
Revised: August 26, 2024
Accepted: September 9, 2024
Published online: December 16, 2024
Processing time: 85 Days and 8.8 Hours
Core Tip

Core Tip: The introduction of cancer immunotherapies, particularly the utilization of monoclonal antibodies that inhibit immune checkpoints, has yielded significant benefits, including enhanced survival rates and a diminished likelihood of adverse effects. However, immune-related adverse events can manifest in certain patients, presenting mild symptoms such as fever, fatigue, headache, rash, arthralgia, and myalgia. In more severe cases, circulatory shock or multiorgan failure can occur, which can be mortal. This editorial examines the possible immunologic mechanisms underlying cytokine release syndrome and the exacerbation of psoriasis in patients receiving anti-programmed death-1 monoclonal antibodies.